- Q4 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 06, 2024$2.48 (-19.48%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2023$1.81 (-8.84%)Earnings
- Q2 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 08, 2023$2.58 (+3.61%)Earnings
- Q1 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 09, 2023$2.73 (+13.75%)Earnings
- Q4 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 08, 2023$1.35 (-11.76%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2022$1.48 (-1.33%)Earnings
- Xeris Biopharma Holdings Inc XP-8121 Call TranscriptOct 20, 2022
- Q2 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 10, 2022$1.93 (+13.53%)Earnings
- Q1 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 11, 2022$1.64 (-8.38%)Earnings
- Q4 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 10, 2022$2.62 (+6.07%)Earnings
- Q3 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 10, 2021$1.9 (-3.06%)Earnings
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone. Thank you for being here. I'm (inaudible) from JPM. We have with us here today, CEO of Xeris Pharma, Paul Edick.
Thank you. Welcome, everybody. I'm going to give you the overview on Xeris, and then we'll have a Q&A. Xeris is a growth-oriented biopharma company committed to improving the lives of -- and developing and commercializing assets in both rare and specialty areas. I would remind everyone to pay attention to our forward-looking statements. Investing is always a risk.
Let's start off with an overview of the company. Xeris has a very diversified revenue base. We have 3 marketed assets, all growing. RECORLEV, I'll talk a little bit about. It's in the launch stage. And this year, we have guided to $105 million -- or 2022, we've guided to $105 million to $110 million. We'll finish at the top end of that range.
We have a specialized commercial platform in endocrinology and in neurology, and we'll go into some of the products. Our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)